Aripiprazole: An FDA Approved Bioactive Compound to treat schizophrenia-A Mini Review.

  title={Aripiprazole: An FDA Approved Bioactive Compound to treat schizophrenia-A Mini Review.},
  author={A. Kumar and H. Singh and Amrita Mishra and A. Mishra},
  journal={Current drug discovery technologies},
  • A. Kumar, H. Singh, +1 author A. Mishra
  • Published 2018
  • Medicine
  • Current drug discovery technologies
  • OBJECTIVE Aripiprazole,a synthetic compound, obtained by chemical modification of the structure of quinolinone is considered as an atypical antipsychotic drug. The present review is an attempt to summarize the updated information related to reported chemistry and pharmacology of Aripiprazole. DEVELOPMENT Aripiprazole, under development by Otsuka Pharmaceutical, was approved by the U.S. Food and Drug Administration (USFDA) in the end months of 2002 to with an aim to treat patients with… CONTINUE READING


    A review of aripiprazole long-acting injection
    • 12
    Aripiprazole, a Novel Atypical Antipsychotic Drug
    • 70
    Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study.
    • 115
    • PDF
    Aripiprazole: from pharmacological profile to clinical use
    • 44
    • PDF
    Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
    • 529
    • PDF